Key facts
- RheumaFinder’s last known valuation is $2.2M (Dec 2023).
- It has raised $300K; the latest was Seed Round in Aug 2025.
- Notable investors include Novalis Biotech.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for RheumaFinder
- ·The full record, as it builds
Funding rounds
No funding rounds for RheumaFinder are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RheumaFinder
Developer of a medical imaging platform designed to detect rheumatic diseases. The company's platform utilizes artificial technology to analyse standard medical images to detect early signs of joint damage, addressing diagnostic delays and underdiagnosis in rheumatic diseases, enabling healthcare practitioners to provide timely interventions for patients.
- Sector
- Healthcare
- HQ
- Ghent, Belgium
- Founded
- 2023
- Employees
- 7
- Website
- rheumafinder.ai/
- Ownership
- Privately Held (backing)
RheumaFinder doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RheumaFinder shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RheumaFinder in its N-PORT filings yet. We sweep new filings monthly.